The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type  by Yuneva, Mariia O. et al.
Cell Metabolism
ArticleThe Metabolic Profile of Tumors Depends on Both
the Responsible Genetic Lesion and Tissue Type
Mariia O. Yuneva,1,* TeresaW.M. Fan,4 Thaddeus D. Allen,1 RichardM. Higashi,4 Dana V. Ferraris,5 Takashi Tsukamoto,5,6
Jose´ M. Mate´s,7 Francisco J. Alonso,7 Chunmei Wang,2 Youngho Seo,3 Xin Chen,2 and J. Michael Bishop1
1G.W. Hooper Research Foundation
2Department of Bioengineering and Therapeutic Sciences
3Department of Radiology and Biomedical Imaging
University of California, San Francisco, San Francisco, CA 94143, USA
4Center for Regulatory and Environmental Analytical Metabolomics, Department of Chemistry, University of Louisville, Louisville,
KY 40208, USA
5Brain Science Institute
6Department of Neurology
Johns Hopkins University, Baltimore, MD 21205, USA
7Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Ma´laga, 29071 Ma´laga, Spain
*Correspondence: mariia.yuneva@ucsf.edu
DOI 10.1016/j.cmet.2011.12.015SUMMARY
The altered metabolism of tumors has been consid-
ered a target for anticancer therapy. However, the
relationship between distinct tumor-initiating lesions
and anomalies of tumor metabolism in vivo has
not been addressed. We report that MYC-induced
mouse liver tumors significantly increase both
glucose and glutamine catabolism, whereas MET-
induced liver tumors use glucose to produce gluta-
mine. Increased glutamine catabolism in MYC-
induced liver tumors is associated with decreased
levels of glutamine synthetase (Glul) and the switch
from Gls2 to Gls1 glutaminase. In contrast to liver
tumors,MYC-induced lung tumors display increased
expression of both Glul and Gls1 and accumulate
glutamine. We also show that inhibition of Gls1 kills
cells that overexpress MYC and catabolize gluta-
mine. Our results suggest that the metabolic profiles
of tumors are likely to depend on both the genotype
and tissue of origin and have implications regarding
the design of therapies targeting tumor metabolism.
INTRODUCTION
Increased consumption and altered metabolism of two major
nutrients, glucose and glutamine, are often observed in tumors
and cancer cell lines (reviewed in Baggetto, 1992; Gatenby
andGillies, 2004; Medina, 2001). Pathways of glucose and gluta-
minemetabolism fuel processes vital for cellular proliferation and
survival and can be controlled by several oncogenes involved in
human cancers. For example, the MYC proto-oncogene regu-
lates the expression of several enzymes of glycolysis, the Krebs
cycle, mitochondrial respiration, and nucleotide synthesis
(http://www.myccancergene.org/), as well as glutamine trans-
porters and glutaminase (Gao et al., 2009; Wise et al., 2008),Cell Mthe first enzyme of glutamine catabolism; hepatocyte growth
factor (HGF)/scatter factor and its tyrosine kinase receptor
MET regulate carbohydrate metabolism (Kaplan et al., 2000;
Perdomo et al., 2008); PI3K/AKT and RAS/MAPK signaling path-
ways, which are initiated by HGF binding to MET (Vogelstein and
Kinzler, 2004), are well-known regulators of cellular metabolism
(reviewed in (Yuneva, 2008); b-catenin, a central player in the
Wnt pathway (Klaus and Birchmeier, 2008), regulates genes
responsible for glutamine synthesis (Cadoret et al., 2002); and
b-catenin activation in mouse liver is associated with altered
expression of proteins regulating glycolysis and mitochondrial
activity (Chafey et al., 2009). These reports provide important
clues to understanding how expression of oncogenes promotes
metabolic changes and indicate that such changes might vary
among tumors carrying distinct oncogenic lesions. However,
most of these studies were either performed in cell lines or
were limited mainly to evaluating protein expression profiles
that do not necessarily reflect the activity of metabolic pathways.
In this study, we used stable isotope-basedmetabolic analysis
to evaluate how glucose and glutamine metabolism is altered
during tumorigenesis initiated by individual oncogenes in vivo.
We also assessed the expression and activity of the main
enzymes regulating the metabolism of these two nutrients. In
order to compare the effect of two distinct oncogenes, we
used well-characterized mouse models of liver cancer induced
by tissue-specific overexpression of either humanMYC (Shachaf
et al., 2004) or MET (Wang et al., 2001). Mouse liver tumors
induced by MYC resemble immature hepatoblastomas with
high mitotic activity (Shachaf et al., 2004; Tward et al., 2005),
whereas tumors induced byMET resemble differentiated human
hepatocellular carcinomas (HCCs) (Tward et al., 2005; Wang
et al., 2001). The tumors induced by MET carry spontaneous
activating mutations of b-catenin (Tward et al., 2007). Abnormal
expression and activity ofMYC (Kaposi-Novak et al., 2009; Thor-
geirsson and Grisham, 2002), activating mutations and
increased expression of MET (Kaposi-Novak et al., 2006; Ueki
et al., 1997), and activating mutations of b-catenin (de La Coste
et al., 1998; Tward et al., 2007) occur frequently in human liver
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Figure 1. Lactate Levels Are Significantly
Increased in MYC-Induced but Not in MET-
Induced Murine Liver Tumors
(A and B) Glucose and lactate levels in tumor and
normal liver tissue extracts measured by enzyme-
based assays. Normal tissue was from wild-type
FVBN mice and transgenic mice kept on doxycy-
cline.
(C and D) Representative profiles of 1H NMR per-
formed on extracts from tumors and adjacent liver
tissues from animals injected with [U-13C]-glucose
(number of animals analyzed is indicated in E). Two
satellite peaks at 1.21 and 1.42 ppm represent fully
labeled 13C-lactate. The profiles were normalized
to the initial dry weight of tissue.
(E) Quantification of 13C-lactate concentration in
the samples from (C) and (D). #p = 0.050 for MET-
induced tumors versus MYC-induced tumors.
(F) Ldha RNA levels estimated by real-time PCR in
the samples outlined in (A) and (B). Mouse b-actin
served as an internal control. One of the FVBN
normal livers was used as a reference.
(G) Ldha expression estimated by immunoblotting
of whole-tissue lysates of normal livers and
tumors. Ponceau staining of membranes was
used to confirm the protein loading.
(H) LDH activity measured in the cytosolic frac-
tions of tumors and normal livers from transgenic
mice kept on doxycycline. All values are given as
the mean ±SD. See also Figure S1.
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Determinants of Tumor Metabolism In VivoTo evaluate whether the effect of oncogenic transformation on
metabolism depends on the tissue context, we used a model
of lung cancer induced by overexpression of MYC (Allen
et al., 2011). Increased expression of MYC family members is
observed in some human lung cancers (Gazzeri et al., 1994;
Yokota et al., 1988), and MYC overexpression in the lungs of
mice causes adenocarcinomas (Allen et al., 2011; Tran et al.,
2008).
We found that glucose and glutamine metabolism in tumors
varies with both the nature of the initiating lesion (MYC or MET)
and the tissue of origin. Moreover, inhibition of Gls1, an isoform
of glutaminase overexpressed in MYC-induced tumors, causes158 Cell Metabolism 15, 157–170, February 8, 2012 ª2012 Elsevier Inc.apoptosis in cells that have high levels
of MYC and use glutamine to fuel the
Krebs cycle. We conclude that metabolic
profiling will be essential to determine the
nature of metabolic alterations in tumors
and to choose proper therapeutics aimed
at these alterations.
RESULTS
MYC and MET Have Different
Effects on Glucose Metabolism
in the Liver
One of the hallmarks of cancer is aerobic
glycolysis (the Warburg effect) associ-
ated with increased consumption of
glucose and increased levels of lactate,
a product of glucose catabolism (War-burg, 1956). Therefore, we first examined whether glucose
metabolism was changed in mouse tumors induced by either
MYC or MET transgenes expressed specifically in the liver of
FVBN mice under the control of a Tet-repressible promoter
(Shachaf et al., 2004; Wang et al., 2001). Expression of the trans-
genes and tumor formation were induced by the removal of
doxycycline from a diet. Transgenic animals kept on a doxycy-
cline diet and wild-type FVBN mice were used as controls.
We found that the levels of glucose were below normal in
tumors induced by either MYC or MET (Figure 1A). Consistent
with this, the expression of glucose-6-phosphatase, one of the
key enzymes of glucose biosynthesis, was decreased in both
Figure 2. Glucose Levels Are Controlled
Differently in Tumors Induced by Either
MYC or MET
(A) PET/CT imaging of 18F-FDG uptake performed
on normal and tumor-bearing animals. After
imaging, tumor presence was confirmed as
demonstrated by photographs under each scan
image. Tumors are indicated by arrows. Images of
representative animals are shown.
(B) 18F-FDG uptake quantified as described in the
Experimental Procedures. The normal group
contained one FVBN mouse and one each of mice
carrying either MYC or MET transgenes and kept
on doxycycline. *p = 0.038 forMET versus normal,
**p = 0.023 forMYC versus normal, and #p = 0.036
for MET versus MYC.
(C and E) RNA levels for glucokinase (C) and Hk2
(E) measured in normal and tumor tissues using
mouse b-actin as an internal control. Results are
normalized as in Figure 1F. Values are given as the
mean ±SD.
(D) Glucokinase expression estimated in the
cytosolic fractions of normal and tumor tissues by
immunoblotting. Ponceau staining was used to
confirm the protein loading.
(F) Hk2 protein levels measured in whole-tissue
lysates from normal and tumor samples by
immunoblotting using b-actin as a loading control.
See also Figure S2 and Table S1.
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gesting that glucose synthesis might be deficient in both types of
tumors. In MYC-induced tumors, decreased levels of glucose
were frequently associated with increased levels of lactate in
comparison with normal liver (Figure 1B). Moreover, lactate
levels in MYC-induced tumors were significantly higher than in
the ostensibly normal liver tissue adjacent to tumors (Figures
S1C and S1D). Although in three out of seven MET-induced
tumors we observed levels of lactate higher than in the adjacent
tissue (data not shown), overall, MET-induced tumors did not
demonstrate a statistically significant increase of lactate levels
in comparison with either normal liver (Figure 1B) or adjacent liver
tissue (Figures S1C and S1D).
In order to test if glucose catabolism contributes to increased
lactate levels in MYC-induced tumors, we administered uni-
formly labeled 13C-glucose, [U-13C]-glucose, to tumor-bearing
animals. Administration of [U-13C]-glucose resulted in increase
of 13C-lactate levels in liver tumors induced by MYC (Figures
1D and 1E and Figure 4C). In contrast,MET-induced tumors dis-
played only slight or no increase in 13C-lactate levels, which
overall was not statistically significant (Figures 1C and 1E and
Figure 4C). These results indicate that increased lactate levels
in MYC-induced tumors may be, at least in part, the result of
increased lactate production from glucose.
Lactate is produced from pyruvate, the end product of glucose
catabolism through glycolysis, by lactate dehydrogenase (LDH).Cell Metabolism 15, 157–170Increased activity of LDH and increased
expression of its A subunit (Ldha), which
favors rapid conversion of pyruvate into
lactate, are observed in human cancers
(Goldman et al., 1964). Unexpectedly,although the levels of Ldha RNA were increased only in MYC-
induced tumors (Figure 1F), the levels of Ldha protein (Figure 1G)
and total LDH activity (Figure 1H) were increased to the same
extent in both types of tumors. This demonstrates that increased
LDH activity is not the only factor responsible for the difference in
lactate levels between tumors induced by the two oncogenes.
To understand why increased LDH activity was accompanied
by higher levels of glucose-derived lactate in MYC-induced
tumors than in MET-induced tumors, we compared glucose
transport and catabolism in both types of tumors. To analyze
glucose transport, we used 18F-fluorodeoxyglucose (FDG) and
positron emission tomography/computed tomography (PET/
CT). Although glucose transport was above normal in both types
of tumors, the intensity of FDG uptake was significantly higher in
MYC-induced tumors than in MET-induced tumors (Figures 2A
and 2B). The significantly higher glucose transport and compa-
rably lower glucose levels in MYC-induced tumors suggest
that these tumors catabolize glucose faster than MET-induced
tumors.
We next compared the regulation of the first step of glucose
catabolism, glucose phosphorylation, in the two types of tumors.
In normal hepatocytes, glucose phosphorylation is catalyzed by
glucokinase, which has a high Km (low affinity) for glucose and, in
its active form, is localized in the cytosol (Bustamante et al.,
2005). We found that glucokinase expression was decreased
in MYC-induced tumors (Figures 2C and 2D). Consistent with, February 8, 2012 ª2012 Elsevier Inc. 159
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Determinants of Tumor Metabolism In Vivothis, we detected glucose-6-phosphorylating activity with a high
Km (17 mM) in the cytosolic fraction of normal liver but not in the
cytosolic fraction ofMYC-induced tumors (Table S1). In contrast
to MYC-induced tumors, decreased expression of glucokinase
in MET-induced tumors (Figures 2C and 2D) was associated
with the emergence of glucose-6-phosphorylating activity in
the cytosolic fraction of these tumors that had both decreased
Km and Vmax compared to normal liver (Table S1). These results
suggest that, although MET-induced tumors may have less
glucokinase in comparison with normal liver, it may be a more
efficient form of glucokinase.
Hexokinase II (Hk2) is a hexokinase isoform that has a low Km
(high affinity) for glucose and can be overexpressed in human
tumors and cancer cell lines (Bustamante et al., 1981). Hk2
localizes both in the cytosol and at the mitochondrial
membrane. Mitochondrial localization of Hk2 may increase
its efficiency (Bustamante et al., 1981). We found that Hk2
expression was significantly increased in tumors induced by
MYC but not in those induced by MET (Figures 2E and 2F).
Consistent with this, glucose-6-phosphorylating activity with
a low Km (0.01–0.08 mM) appeared in the mitochondrial
fraction and increased 10-fold in the cytosolic fraction of
MYC-induced tumors, while staying unchanged inMET-induced
tumors (Table S1).
In addition to Hk2, tumors induced byMYC, but notMET, had
increased expression of liver- and platelet-specific subunits of
phosphofructokinase (Figure S2), one of the key glycolytic
enzymes. Higher abundance of these subunits in the holoen-
zyme contributes to acceleration of glucose catabolism (Vora
et al., 1985).
Altogether our results suggest that glucose transport and
catabolismmay be increased in both types of tumors in compar-
ison with normal liver. However,MYC-induced liver tumors have
significantly higher glucose uptake and catabolism than MET-
induced liver tumors, which may explain why MYC-induced
tumors have significantly increased levels of lactate whereas
MET-induced tumors do not.
MYC and MET Differently Affect Glutamine Metabolism
in the Liver
Glutamine is another major nutrient whose metabolism can be
altered during tumorigenesis (Marquez et al., 1989). Nuclear
magnetic resonance (NMR) analysis revealed that glutamine
levels were undetectable in MYC-induced tumors (Figure 3A),
whereas glutamine levels increased almost 2-fold in MET-
induced tumors compared to normal liver (Figures 3B and 3C).
To reconcile the differences in the levels of glutamine between
tumors induced by the two oncogenes, we evaluated the
expression of two enzymes: glutamine synthetase (Glul), which
catalyzes the ligation of ammonia and glutamate to produce
glutamine, and phosphate-dependent glutaminase, which is
responsible for glutamine catabolism into glutamate. Liver-type
glutaminase (Gls2) is expressed in adult periportal hepatocytes,
brain, and pancreas, whereas kidney-type glutaminase (Gls1) is
expressed in embryonic hepatocytes, in most adult tissues with
the exception of the postnatal liver, and in some cancer cell lines
(Curthoys and Watford, 1995; Perez-Gomez et al., 2005). We
found that in MYC-induced tumors the expression of Glul was
suppressed in comparison with normal liver (Figure 3D and Fig-160 Cell Metabolism 15, 157–170, February 8, 2012 ª2012 Elsevier Inure S3A), and the expression of the Gls2 isoform of glutaminase
was replaced by the Gls1 isoform (Figures 3D and 3E and Fig-
ure S3B). Importantly, the shift in glutaminase isoforms was
associated with an increase in glutaminase activity (Figure 3F).
Finally, MYC-induced tumors exhibited increased expression
of the high-affinity glutamine transporter Slc1a5 (Figure 3D and
Figure S3C), which is thought to supply cancer cell lines with
amounts of glutamine sufficient for its increased catabolism
(Bode, 2001). These results indicate that glutamine synthesis is
decreased in MYC-induced tumors, whereas its transport and
catabolism are increased.
In contrast toMYC-induced tumors,MET-induced tumors had
increased expression of Glul (Figure 3D and Figure S3A), which
was consistent with the presence of activating mutations in
b-catenin (Tward et al., 2007), a transcriptional activator for
Glul (Cadoret et al., 2002). Moreover, in MET-induced tumors
Gls2 expression was decreased (Figure 3D and Figure S3B),
Gls1 was not expressed (Figures 3D and 3E), and the expression
of Slc1a5 was only slightly higher than normal (Figure 3D and
Figure S3C). Consistent with the expression pattern of gluta-
mine-metabolizing enzymes, administration of uniformly labeled
13C-glutamine, [U-13C]-glutamine, to tumor-bearing mice re-
sulted in significant buildup of 13C-glutamine in MET-induced
tumors (Figure 4D, right panel), indicating that glutamine was
transported into tumors, but its catabolism was significantly
decreased in comparison with normal liver.
One of the main substrates for glutamine biosynthesis is
glucose. Administration of [U-13C]-glucose resulted in increased
levels of 13C-glutamine in MET-induced tumors (Figure 3G and
Figure 4C, left panel). Together these results indicate that in
MET-induced tumors, increased consumption of glucose contri-
butes to increased glutamine biosynthesis, and the elevated
levels of glutamine could result from both increased synthesis
and repressed catabolism. We conclude that glutamine catabo-
lism is increased in MYC-induced tumors, whereas glutamine
production is increased in MET-induced tumors.
MYC-Induced Tumors Have Increased Synthesis
of Krebs Cycle Intermediates
Since glucose and glutamine are the main fuels of the Krebs
cycle, we compared total levels of the Krebs cycle intermediates
(fumarate, malate, and citrate) and related metabolites (gluta-
mate and aspartate) in the two types of tumors and normal liver.
The levels of all these compounds were increased in MYC-
induced but not in MET-induced tumors (Figures 3A and 3B
and Figures 4A and 4B). Moreover, administration of either
[U-13C]-glucose or [U-13C]-glutamine resulted in increased
levels of 13C-citrate, 13C-glutamate, and 13C-aspartate in MYC-
induced tumors (Figures 4C and 4D, Figures S4A and S4B).
This contrasted with MET-induced tumors, which displayed
either insignificant or no changes (Figures 4C and 4D, Figures
S4A and S4B). These results suggest that increased transport
and catabolism of both glucose and glutamine in MYC-induced
tumors contribute to the synthesis of Krebs cycle intermediates,
which is significantly enhanced in comparison with normal liver
and MET-induced tumors.
Injection of [U-13C]-glutamine also resulted in increased incor-
poration of 13C into lactate in MYC-induced tumors (Figure 4D,
right panel), indicating that increased catabolism of glutaminec.
Figure 3. Glutamine Metabolism Is Different in Liver Tumors Induced by Either MYC or MET
(A and B) Glutamine levels determined by NMR in tumors and normal livers from transgenic mice kept on doxycycline. Representative 1H NMR profiles of normal
livers and tumors are shown (at least four animals per group). Glutamine peaks are in 2.42–2.47 ppm region, and glutamate peaks are in 2.32–2.37 ppm region.
The profiles were normalized to the initial dry weight.
(C) Glutamine concentration quantified in normal livers and MET-induced tumors based on 1H-NMR data in (B).
(D) Expression of indicated proteins evaluated by immunoblotting of whole-tissue lysates using b-actin as a loading control.
(E) Gls1 RNA levels measured in normal and tumor tissues using mouse b-actin as an internal control.
(F) Phosphate-dependent glutaminase activity measured in the mitochondrial fraction of MYC-induced tumors and normal livers from transgenic mice kept on
doxycycline. All values are given as the mean ±SD.
(G) Detection of 13C-labeled glutamine by 1H-13C heteronuclear single quantum coherence spectroscopy (HSQC) NMR performed on extracts of tumor-adjacent
and tumor tissues from animals injected with [U-13C]-glucose (5 animals per group). The representative HSQC spectra are shown. 13C-4-glutamine peak is at
2.45 ppm. Consistent with glutamine depletion, a corresponding 13C-4-glutamine peak was not observed inMYC-induced tumors. The profiles were normalized
to the initial dry weight of tissue. See also Figure S3.
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Figure 4. Catabolism of Glucose and Glutamine Contributes to Increased Synthesis of Krebs Cycle Intermediates in MYC-Induced Liver
Tumors
(A and B) The levels of Krebs cycle intermediates measured in tissue extracts by GC-MS. Values are given as the mean ±SD.
(C and D) The representative spectra of 1H-13C HSQCNMR performed on extracts of tumor-adjacent and tumor tissues from animals injected with either [U-13C]-
glucose (C) or [U-13C]-glutamine (D) (at least three animals per group). The profiles were normalized to the initial dry weight. Glc, glucose; G6P, glucose-6-
phosphate; Glu, glutamate; GSH, reduced glutathione; GSSG, oxidized glutathione; Gln, glutamine; Asp, aspartate; Suc, succinate; Ala, alanine; Lac, lactate. See
also Figure S4.
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Determinants of Tumor Metabolism In Vivomay contribute to the increased lactate levels observed in these
tumors. However, currently we cannot discern whether labeled
lactate was produced from glutamine through glutaminolysis162 Cell Metabolism 15, 157–170, February 8, 2012 ª2012 Elsevier In(DeBerardinis et al., 2008) or was the result of increased
catabolism of glucose that was derived from [U-13C]-glutamine
through gluconeogenesis.c.
Figure 5. Metabolism ofMYC-Induced Lung
Tumors Differs from Metabolism of MYC-
Induced Liver Tumors
(A) Lactate levels measured by 1H NMR in lung
tumors induced by MYC (Tumor) and either adja-
cent lung lobes from the same animals (Adjacent
lung) or normal lungs from mice with MYC trans-
gene kept without doxycycline (Normal). Values
are given as the mean ±SD.
(B and D) The levels of indicated proteins esti-
mated by immunoblotting in whole-tissue lysates
using b-actin as a loading control.
(C) Glutamine levels in tissue extracts determined
by GC-MS. Values are given as the mean ±SD.
(E–I) Expression of Glul examined by immuno-
chemistry in normal lung (E),MYC-induced tumors
(F–H), and adjacent lung (I). Expression of Glul is
apparent in bronchial epithelium of normal lung, in
tumor cells, and in infiltrating immune cells of
tumor-adjacent lungs (indicated by arrows).
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Determinants of Tumor Metabolism In VivoTissue Context Affects the Outcome of Metabolic
Reprogramming by MYC
To evaluate if metabolic changes induced by oncogenic transfor-
mation are tissue specific, we analyzed the main pathways of
glucose and glutamine metabolism in lung adenocarcinomas
induced by MYC (Allen et al., 2011). Expression of MYC was
driven specifically in pneumocytes of FVBN mice by a Tet-acti-
vated promoter by keeping mice on a doxycycline diet (Allen
et al., 2011; Tran et al., 2008). Normal lungs from wild-type mice
and mice fed a diet without doxycycline were used as controls.
We found that the levels of lactate (Figure 5A) as well as
expression of both Hk2 and Ldha (Figure 5B) were increased in
lung tumors induced byMYC. This suggested that, similar to liver
tumors, MYC-induced transformation was associated with
increased glucose catabolism into lactate in lung tumors. In
contrast to liver tumors, however, lung tumors induced by
MYC had elevated levels of glutamine (Figure 5C).
Although expression of Gls1 was increased in MYC-induced
lung tumors, expression of Glul also appeared to be aboveCell Metabolism 15, 157–170normal in three out of four lung tumors
(Figure 5D). Immunohistochemical anal-
ysis revealed that in normal lungs Glul
expression was restricted to bronchial
epithelium (Figure 5E), whereas in lung
tumors Glul was highly expressed in
tumor cells (Figures 5F–5H). The expres-
sion of Gls2 in normal lungs was lower
than in the liver and did not change in
lung tumors (Figure 6A and data not
shown). By analogy with previous experi-
ments conducted on human lung cancer
patients infused with [U-13C]-glucose
(Fan et al., 2009), increased glutamine
production in MYC-induced mouse lung
tumors might be the result of increased
glucose conversion into glutamine.
Although glutamine catabolism may also
be increased in lung tumors due to theincreased Gls1 expression, increased Glul expression could
override increased Gls1 expression and account for increased
net glutamine levels.
Increased levels of Glul protein and glutamine were also
observed in ostensibly normal lung tissue adjacent to mouse
tumors (Figures 5C and 5D). Immunohistochemical analysis
showed that Glul was expressed in immune cells infiltrating the
normal tissue (Figure 5I), which could account at least in part
for the increased levels of Glul and glutamine.
Together these data demonstrate that, although some mech-
anisms that regulate metabolic pathways in MYC-induced liver
tumors are similarly altered in MYC-induced lung tumors,
tissue-specific differences in the outcome do exist.
MYC Sensitizes Cells to Inhibition of Glutaminase
We have previously demonstrated that glutamine metabolism
through the Krebs cycle is required for the survival of cells that
overexpress MYC (Yuneva et al., 2007). Since the shift from
Gls2 to Gls1 accompanies the increase in glutamine catabolism, February 8, 2012 ª2012 Elsevier Inc. 163
Figure 6. GLS1 Inhibitors Affect Glutamine Catabolism through the Krebs Cycle
(A) IMR90-ERMYC and HA1E-MYCER cells were incubated for 24 hr with either OHT (MYCOn) or 0.1% ethanol (MYCOff). Expression of GLUL, GLS2, and GLS1
was detected in whole lysates of these cells, normal liver and lung as well as ofMYC-induced liver and lung tumors by immunoblotting using b-actin as a loading
control. Asterisk indicates crossreactive band recognized by anti-Gls2 antibody in human cell lines.
(B and C) IMR90-ERMYC cells with induced MYC activity were incubated with 2 mM [U-13C]-glutamine and indicated concentrations of BPTES for 12 hr. DMSO
(0.1%) was used as a vehicle control. Absolute concentrations (B) and 13C isotopologue enrichment (C) of indicated compounds were measured by GC-MS. In
(C), metabolate+0 represents monoisotopic or unlabeled isotopologue, while metabolite+1–5 are isotopologues with one to five 13C atoms. The results were
referenced to the initial dry weight of cell pellet. An average of two replicate samples is presented. The experiment was repeated twice.
(D) IMR90-ERMYC cells with induced MYC were incubated with 2 mM 15N2-glutamine and indicated concentrations of BPTES, 20767, or DON. Incorporation of
15N into adenine nucleotides (AXP) was evaluated by 1H NMR. The profiles are referenced to the dry weight of cell pellet and the internal standard concentration.
The representative profiles from two independent experiments are presented. See also Figures S5 and S6.
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Determinants of Tumor Metabolism In Vivothrough the Krebs cycle in MYC-induced mouse liver tumors
(Figure 3D and Figure 4D), we reasoned that Gls1 could be
a plausible target for eliminating cells that catabolize glutamine164 Cell Metabolism 15, 157–170, February 8, 2012 ª2012 Elsevier Inand overexpress MYC. To test this possibility, we used normal
human lung fibroblasts (IMR90) and immortalized human kidney
epithelial cells (HA1E) expressing conditional versions of MYCc.
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Determinants of Tumor Metabolism In Vivo(IMR90-ERMYC and HA1E-MYCER) that can be activated by
4-hydroxytamoxifen (OHT) (Yuneva et al., 2007), as well as
HA1E cells that constitutively overexpress wild-type MYC
(HA1E-MYC). We found that all of these lines had metabolic
features resembling those of MYC-induced liver tumors, irre-
spective of the presence or absence of active ectopic MYC,
namely (1) levels of GLS1 comparable to those in the tumors (Fig-
ure 6A and Figure 7D), (2) prevalence of GLS1 over GLS2 expres-
sion (Figure 6A), and (3) low levels of GLS2 and GLUL (Figure 6A).
Moreover, all of the cell lines had glucose as the primary source
of lactate (Figures S5A and S5C, and data not shown) and gluta-
mine as the principal fuel for the Krebs cycle (Figures S5B and
S5D and data not shown). We attribute this phenotype to the
relative abundance of endogenous MYC in the cell lines (Fig-
ure 7D and data not shown), which could represent adaptation
to sustained propagation in vitro. It remains the case, however,
that a further increase in MYC activity increases the sensitivity
of HA1E and IMR90 cells to glutamine deprivation (Yuneva
et al., 2007). These results indicate that different levels of MYC
might be required to change a metabolic phenotype of the cells
and to make them dependent on glutamine for survival. We
proceeded to test the response of IMR90 and HA1E cells to
inhibition of GLS1 in the absence and presence of augmented
MYC activity.
We used an inhibitor of GLS1, bis-2-(5-phenylacetoamido-
1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (Robinson et al.,
2007), and its water-soluble analog, 20767 (Erdmann et al.,
2007). Together with increasing the levels of glutamine, both
BPTES and 20767 decreased the levels of glutamate and other
Krebs cycle intermediates and their products (Figure 6B, Fig-
ure S6A, and data not shown), as well as the incorporation of
glutamine-derived 13C into these compounds (Figure 6C, Fig-
ure S6B, and data not shown) in IMR90-ERMYC cells incubated
either with or without OHT. Importantly, unlike 6-diazo-5-oxo-L-
norleucine (DON), a glutamine analog and inhibitor of both
glutaminase and amidotransferases, neither BPTES nor 20767
inhibited the incorporation of glutamine-derived 15N into adenine
nucleotide species (Figure 6D). These results indicate that both
BPTES and 20767 inhibit glutaminase activity but spare amido-
transferase activities involved in nucleotide biosynthesis.
Both BPTES and 20767 induced apoptosis in IMR90-ERMYC
and HA1E-MYCER cells in a MYC-dependent manner (Fig-
ure 7A). Moreover, HA1E-MYC cells were more sensitive to
BPTES treatment than HA1E transduced with a vector control
(HA1E-Vector) (Figure 7B). Silencing GLS1 expression by two
independent shRNAs in HA1E-MYC and HA1E-Vector cells
confirmed that the BPTES effect on the viability of cells with
ectopically expressed MYC was due to inhibition of GLS1
activity (Figure 7C). Treatment with 20767 also killed human
Burkitt’s lymphoma cell lines that overexpress MYC as a conse-
quence of well-characterized translocations ofMYC (Figure 7E).
In contrast to MYC, ectopic expression of H-RASV12 did not
sensitize HA1E cells to either glutamine deprivation or inhibition
of GLS1 activity (Figures 7B and 7C).
We conclude that MYC but not H-RASV12 exhibits a synthetic
lethal interaction with the inhibition of GLS1 activity and that
overexpression of MYC may be a valuable biomarker for sensi-
tivity to such inhibition. Moreover, specific inhibition of gluta-
minase might be less toxic than a therapy employing glutamineCell Manalogs that may interfere with nucleotide biosynthesis and
thus induce DNA damage (Hastak et al., 2008).
DISCUSSION
Determinants of Tumor Metabolism
Here we demonstrate that liver tumors induced by eitherMYC or
MET have distinct metabolic phenotypes. Moreover, the metab-
olism of MYC-induced liver tumors differs from the metabolism
of MYC-induced lung tumors. Some of the metabolic changes
that are observed during MYC-induced tumorigenesis in both
liver and lung, including increased expression of Hk2, Ldha,
and Gls1, may be the result of MYC overexpression itself (Gao
et al., 2009; Osthus et al., 2000; Wise et al., 2008). On the other
hand, there are differences between liver and lung tumors
induced by MYC that may be due to other tumorigenic events
or determined by tissue-specific functions. For example, MYC-
induced lung tumors are distinguished from those in the liver
by increased expression of Glul. Whereas, to the best of our
knowledge, regulation of Glul expression by MYC has never
been reported, Glul is a well-known transcriptional target of
b-catenin (Cadoret et al., 2002), which is activated in a subset
of human lung cancers (Sunaga et al., 2001). However, our
immunohistochemical analysis revealed that in MYC-induced
lung tumors, b-catenin is located at the cytoplasmic membrane
rather than in the nucleus (data not shown), indicating that the
protein had not been activated by mutation and is not likely the
cause of Glul overexpression. During inflammation, expression
of Glul can be stimulated by glucocorticoids in lung epithelial
cells (Abcouwer et al., 1996). This suggests that increased Glul
expression in MYC-induced lung tumor cells may be induced
by tumor-associated inflammation.
Although in liver tumors the expression of both Gls1 and Glul is
regulated at the RNA level (Figure 3 and Figure S3A), the expres-
sion of these proteins in lung tumors is regulated at the protein
level (data not shown). This observation is consistent with the
ability of MYC to regulate protein expression posttranscription-
ally (Chang et al., 2008) and with variations in the regulation of
Gls1 expression by MYC among cell lines of different origin
(Gao et al., 2009; Wise et al., 2008). It also suggests that the
mechanism of regulation of metabolic enzyme expression either
by MYC or other factors involved in tumorigenesis is context
specific.
Increased Lactate Levels and LDH Activity Do Not
Always Correlate in Tumors
Increase in glucose consumption and lactate production even in
the presence of normal oxygenation is a widely recognized char-
acteristic of tumor metabolism. Our results show that, although
the activity of LDH, the enzyme responsible for pyruvate conver-
sion into lactate, was increased to the same extent in liver tumors
induced by eitherMYC orMET (Figure 1H), a significant increase
in lactate levels was only observed inMYC-induced tumors (Fig-
ure 1B and Figure S1C). This demonstrates that increased LDH
activity does not necessarily correlate with increased lactate
levels in tumors.
In both MYC- and MET-induced liver tumors, the activities of
glucose transport and glucose phosphorylation were higher
than in normal liver (Figure 2 and Table S1), indicating thatetabolism 15, 157–170, February 8, 2012 ª2012 Elsevier Inc. 165
Figure 7. GLS1 Inhibitors Induce MYC-Dependent Apoptosis
(A) MYC activity was induced in HA1E-MYCER and IMR90-ERMYC cells as described in Figure 6A. Cells then were treated with indicated concentrations
of BPTES or 20767 or with 5 mM DON. DMSO (0.1%) was used as a vehicle control for the experiments with BPTES. HA1E-MYCER cells were treated for
36 hr, and IMR90-ERMYC cells were treated for 48 hr and the percentage of apoptotic nuclei was scored. The average of three independent experiments is
presented ±SD.
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pyruvate may be increased in both types of tumors (Marin-
Hernandez et al., 2006). In contrast toMYC-induced liver tumors,
however, the increase of glucose transport and catabolism
in most MET-induced tumors may not be sufficient to
produce amounts of pyruvate and NADH that would saturate
the enzymes that compete with LDH for these substrates
(Spriet et al., 2000). Moreover, increased glutamine catabolism
observed in MYC-induced tumors may also contribute to
creating a surplus of pyruvate available to LDH (DeBerardinis
et al., 2008); and MYC and MET may have different effects on
the activity of pyruvate-utilizing enzymes that compete with
LDH, as well as the redox state of the cells. Nevertheless,
increased expression of LDH in MET-induced tumors may
serve to ensure that once any surplus of pyruvate becomes
available, it is efficiently converted into lactate regenerating
NAD+ required for the turnover of glycolysis. The increased
expression of LDH observed in either MYC or MET-induced
tumorsmay also play a role independent of itsmetabolic function
(Ronai, 1993).
The Role of Metabolic Changes inMYC- and
MET-Induced Tumorigenesis
The combination of glucose catabolism into lactate and gluta-
mine catabolism through the Krebs cycle was suggested to
support rapid proliferation of tumor cells by simultaneously
supplying them with ATP and biosynthetic precursors (DeBerar-
dinis et al., 2008; McKeehan, 1982). Indeed, MYC-induced liver
tumors, which have increased lactate production from glucose
and increased catabolism of both glucose and glutamine
through the Krebs cycle, demonstrate higher proliferation than
MET-induced liver tumors (Figure S7A), which do not signifi-
cantly increase glucose catabolism into lactate and produce
rather than catabolize glutamine.
Elevated intracellular levels of glutamine were proposed
to prime cells for activation of the mammalian target of rapa-
mycin complex 1 (mTORC1), one of the major regulators of
cell growth and proliferation (Nicklin et al., 2009). Thus, in-
creased GLUL expression and the resulting elevated intra-
cellular glutamine levels in MET-induced liver tumors and
MYC-induced lung tumors might serve to ensure mTORC1
activity in the absence of exogenous glutamine and give tumor
cells an advantage in nutrient-restricted conditions. Consistent
with this hypothesis, glutamine deprivation did not affect phos-
phorylation of S6 (P-S6), a marker of mTORC1 activity, in Huh7
or HEPG2 cells, which have high levels of GLUL (Figure S7B).
In contrast, glutamine deprivation caused a reduction of P-S6(B) HA1E cells transduced with either empty vector or vectors carrying either MY
indicated concentrations of BPTES for 24 hr. Apoptosis was scored in three ind
sentative of two independent experiments is shown.
(C) HA1E-derived cell lines were infected with lentiviruses expressing either a scra
and shGLS1_2). Cells were collected 36 or 48 hr after the infection, GLS1 express
apoptotic nuclei. For each shRNA the experiment was repeated at least twice
exceptional level of cell death induced by lentiviral infection observed specificall
(D) The ectopic expression of MYC and H-RASV12, as well as expression of ERK
Increased expression of P-ERK indicates increased activity of RAS.
(E) Indicated Burkitt’s lymphoma cell lines were cultured in the presence of 150 mM
of two independent experiments is shown.
Cell Min SK-HEP-1 cells, which do not have detectable GLUL expres-
sion (Figure S7B).
Synthetic Lethal Interaction between MYC
and Inhibition of GLS1
Our present work demonstrates that inhibitors of Gls1 might
eliminate tumor cells that overexpress MYC and catabolize
glutamine to feed the Krebs cycle. In most of the MYC-induced
lung tumors we examined, however, increased expression of
Gls1 was accompanied by increased expression of Glul (Fig-
ure 5), which indicates that these tumors may both catabolize
and produce glutamine. Increased expression of Glul can be
sufficient to protect cells from glutamine deprivation (Kung
et al., 2011). However, whether it can render cells that overex-
press MYC resistant to GLS1 inhibition remains to be investi-
gated. The contribution of various anaplerotic pathways that
can contribute to the Krebs cycle (Cheng et al., 2011) should
also be taken into account when identifying malignancies that
might benefit from inhibiting glutaminase activity.
Since the GLS2 isoform of glutaminase is responsible for
glutamine catabolism in normal liver, selective inhibition of
GLS1 offers an opportunity to target glutamine catabolism of
liver tumors that overexpress MYC without affecting the
metabolism of normal liver. On the other hand, GLS1 inhibition
may be toxic to other normal tissues that express GLS1, such
as kidney, intestine, lung, and brain. However, our results
demonstrate that expression of GLS1 in IMR90 and HA1E cells
does not expose the cells to the lethal effect of GLS1 inhibition
unless high levels of MYC are present, indicating that normal
tissues with normal MYC levels may not be affected by GLS1
inhibitors. One of the well-known consequences of MYC overex-
pression is the induction of apoptosis by shifting the balance
between prosurvival and prodeath signals (Meyer and Penn,
2008). The reduction in the Krebs cycle activity in response
to GLS1 inhibition (Figure 6 and Figure S6) may represent a
stress signal that can unleash the proapoptotic activity of MYC
when the gene is expressed above a certain threshold (Murphy
et al., 2008).
Glutamine is a substrate for multiple metabolic reactions, and
glutaminase catalyzes only one of them. Indeed, complete depri-
vation of glutamine is more efficient in killing cells with high levels
ofMYC than inhibition of glutaminase (Figure 7B). This suggests
that other pathways of glutamine metabolism may provide the
opportunity for additional synthetic lethal interactions with the
overexpression of MYC (DeBerardinis and Cheng, 2010; Mates
et al., 2006). Identification of such interactions might provide
additional therapeutic opportunities.C or H-RASV12 were either incubated in glutamine-free media or treated with
ependent replicate samples. The values are given as the mean ±SD. A repre-
mbled shRNA (shScr) or two independent shRNAs targeting GLS1 (shGLS1_1
ion was evaluated by immunoblotting, and apoptosis was scored by counting
. Transduction with empty pLKO.1 vector (EV) was used to account for the
y in HA1E cells with ectopic expression of MYC.
, P-ERK, and GLS1, was estimated by western blotting in whole-cell lysates.
20767. Cell death was analyzed by Annexin V and PI staining. A representative
etabolism 15, 157–170, February 8, 2012 ª2012 Elsevier Inc. 167
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Animals
Oncogene-driven liver (Shachaf et al., 2004; Wang et al., 2001) and lung (Allen
et al., 2011; Tran et al., 2008) tumors were generated as described previously.
See the Supplemental Experimental Procedures for more details.
For isotopomer analysis of either glucose or glutamine metabolism, tumor-
bearing mice were injected with either 20 mg of [U-13C]-glucose (Cambridge
Isotope Laboratories) (Fan et al., 2011) or with three consecutive injections
(with a 15 min interval) of [U-13C]-glutamine, 7 mg each (Cambridge Isotope
Laboratories) i.v. Mice were sacrificed 15 min after the last injection. The
percent of 13C enrichment in either glucose or glutamine was comparable
between tumor-free liver tissue and tumors from animals with either MYC- or
MET-induced liver tumors. The percent of 13C enrichment in glucose was
6% ± 2%. The percent of 13C enrichment in glutamine varied between 13%
and 42% depending on an individual animal. Samples of tumor and adjacent
liver tissue were snap frozen in liquid nitrogen. All experiments were performed
according to protocols approved by the Committee on Animal Research at the
University of California, San Francisco.
Cell Culture
Primary IMR90 human lung fibroblasts and immortalized HA1E human kidney
epithelial cells expressing ER-MYC or MYC-ER, respectively, were described
previously (Yuneva et al., 2007). HA1E cells with ectopic expression ofMYC or
H-RASV12 were generated by transduction with the retroviral vector pMaRX-
puro (Hannon et al., 1999) carrying either MYC or H-RASV12 as described
previously (Faleiro and Lazebnik, 2000). See the Supplemental Experimental
Procedures for the detailed description of culture, treatment conditions, and
sequence of shRNAs.
Metabolite Profiling
All frozen tissue samples for metabolite analysis were pulverized and lyophi-
lized. Frozen cell pellets were lyophilized. Metabolites were extracted and
analyzed by NMR and gas chromatography-mass spectrometry (GC-MS) as
described previously (Fan, 2010; Fan et al., 2009). See the Supplemental
Experimental Procedures for more details.
18F-FDG PET/CT Imaging
The animal handling and preparation protocols followed established
procedures to obtain consistent PET results (Fueger et al., 2006) (see the
Supplemental Experimental Procedures for more details). For quantitative
assessment, volumes of interest (VOIs) were placed in liver (cylinder having
5 mm diameter with 5 mm height) involving tumors when present, and in
brain (cylinder having 3 mm diameter with 3 mm height) mostly involving
cerebellum. The uptake in the liver VOI was normalized to the uptake in the
brain VOI.
Enzyme Assays
A mitochondrial fraction was isolated from freshly excised normal livers or
tumors as described previously (Frezza et al., 2007). Cytosol was further sepa-
rated from microsomes by centrifugation at 103,000 g for 60 min. LDH activity
was measured in the cytosolic fraction, glucose-6-phosphorylating activities
were measured in cytosolic and mitochondrial fractions, and phosphate-
dependent glutaminase activity was measured in mitochondrial fractions.
See the Supplemental Experimental Procedures for more details.
Quantitative PCR Analysis and Western Blotting
Protocols, TaqMan Gene Expression Assays, and antibodies are described in
the Supplemental Experimental Procedures.
Statistical Analysis
Statistical analysis was performed by applying a two-tailed Student’s t test.
For the experiments in which concentration of total and 13C-labeled lactate
and glutamate were compared in tumors and adjacent liver tissue (Figure 1E,
Figures S1C and S4), paired Student’s t test was used. For all other analysis,
unpaired Student’s t test was used.168 Cell Metabolism 15, 157–170, February 8, 2012 ª2012 Elsevier InSUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.12.015.
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